ArticleJournal of fluorescence2025
Thermo-responsive Fluorescent Nanopolymer Delivery Platform for Treatment of Diffuse Large B-cell Lymphoma (DLBCL).
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive diffuse malignant proliferative disease of the lymphatic system. Patients usually present with progressive lymph node enlargement and/or extra-lymph node lesions and require early treatment upon diagnosis. Most of the patients are in stage III or IV at the time of diagnosis and about 40% of the patients are difficult to cure. In this study, we developed a novel drug delivery platform using poly(ε-caprolactone)-tetraphenylethylene (PCL-TPE). This fluorescent polymer, combined with a solid-state dye, exhibits temperature-dependent fluorescence. We loaded the synthesized ethyl 2-amino-4-(4-methylthiophen-2-yl)-5,6,7,8-tetrahydro-2 H-chromene-3-carboxylate (compound 1) onto PCL-TPE, creating PCL-TPE@1. By treating human lymphoma cells, we found that PCL-TPE@1 was able to effectively reduce the migratory ability of lymphoma cells by inhibiting the expression of PRMT6. This platform is easy to synthesize, offers thermo-responsive fluorescence, flexibility, and biocompatibility, making it suitable for biomedical drug delivery and smart devices.
Indexed as
Identifiers
39786693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.